TFS Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

TFS Capital’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-44,666	Closed	-$1.81M	–	1260
2016 Q1	$1.81M	Buy	+44,666	New	+$1.54M	0.26%	91
2015 Q3	–	Sell	-40,913	Closed	-$1.02M	–	1108
2015 Q2	$1.02M	Sell	40,913 -24,992	-38%	-$557K	0.1%	333
2015 Q1	$1.51M	Sell	65,905 -8,334	-11%	-$210K	0.15%	210
2014 Q4	$2M	Buy	74,239 +54,686	+280%	+$941K	0.19%	141
2014 Q3	$229K	Sell	19,553 -7,452	-28%	-$94K	0.02%	832
2014 Q2	$420K	Buy	27,005 +14,698	+119%	+$211K	0.03%	709
2014 Q1	$242K	Buy	+12,307	New	+$209K	0.02%	1116

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

TFS Capital's FPRX Position: Q2 2016 in Review

TFS Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2016, closing a stake of 44,666 shares — an estimated $1.81M sold.

TFS Capital first reported a position in FPRX in Q1 2014 and held it in 7 quarters. The position peaked at $2M in Q4 2014. 170 funds tracked by Wall St. Rank hold FPRX as of Q2 2016.

TFS Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
TFS Capital sold 44,666 Five Prime Therapeutics, Inc. shares in Q2 2016, an estimated $1.81M.
TFS Capital first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 7 quarters.
TFS Capital's Five Prime Therapeutics, Inc. position peaked at $2M in Q4 2014.
170 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.